Genocore-Biotech.com Announce License Agreement to Develop Novel Inhibitor of Vascular Protein
Based on these data Genocore-Biotech.com will assume responsibility for late stage development and worldwide commercialization.
<p><strong>Shenzhen; 28, December 2015:</strong> Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs) and Fc-fusion protein drugs, today announced an agreement for the further development of a novel, oral small molecule inhibitor of Vascular Protein 1, a cell molecule that may be effective in the treatment of inflammatory diseases. The inhibitor is currently in phase II clinical development.</p> <p align="center"><img title="logo Genocore-Biotech-com" src="http://oi67.tinypic.com/20gmlvp.jpg" alt="logo Genocore-Biotech-com" /></p> <p align="/center"> </p> <p>Under the terms of the agreement, Genocore Biotech is granted an exclusive license to develop and commercialize the compound. In a novel collaboration model, Genocore Biotech will conduct additional phase II studies to further define the therapeutic potential of the inhibitor. Based on these data Genocore Biotech will assume responsibility for late stage development and worldwide commercialization.</p> <p>“This agreement is a novel model where regulatory responsibility and trial sponsorship will only transition upon the success of additional clinical studies,” said Mr. Wang Yen Horng, president and CEO of Genocore Biotech. “A dedicated and very experienced team located at the Genocore Biotech Innovation Center in Shenzen, will drive the development most efficiently from our side.”</p> <p>"This agreement will allow our companies to fully explore the significant and far-reaching potential of this novel inhibitor. Genocore Biotech’s expertise in drug development and proven success in commercialization will allow us to fully explore the unique attributes of this important molecule and the therapeutic benefits it may provide in the future." continued Mr. Yen Horng.</p> <p><strong>About Genocore-Biotech.com:</strong></p> <p><strong><a title="Genocore-Biotech.com" href="http://genocore-biotech.com/en/">Genocore-Biotech.com</a></strong> is an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs) and Fc-fusion protein drugs. With a total investment of about 95 million USD, about 110 employees and R&D lab, Process Development lab, Analytical & Quality center, and a cGMP clinical production facility the firm is a respectable player in the medical industry. Genocore Biotech has a highly experienced and well-integrated expert team whose expertise covers all the key steps of mAb drug research and development. They have on average 15-20 years of hand-on working experience at leading western biopharmaceutical companies.</p> <p><strong>For Media Contact:</strong></p> <p>Company: Genocore-Biotech.com</p> <p>Address: Excellence Century Plaza</p> <p>Tower 1, Fuhua 3rd Road, Futian District</p> <p>Shenzhen, People's Republic of China</p> <p>Tel: +86 755 330 595 45</p> <p>Email: firstname.lastname@example.org</p>